Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Coeptis Therapeutics, Inc.NASDAQ: COEP

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $704.25K fell 88.5% year over year, behind the -18.6% change in trailing-twelve-month financing cash flow. Sequentially, it fell 71.3% from the prior quarter. Over 3 fiscal years it compounded at +35.8% a year.

Context

  • Financing cash flow amounted to 1008.4% of revenue in FY2025.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -88.5% toward the trailing-twelve-month pace of -18.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$704.25K-71.3% QoQ
Last fiscal yearDec 2025
$13.74M+140.6% YoY
LTMMar 2026
$8.35M-18.6% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-88.5%——
1 year+140.6%——
3-year CAGR+35.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
13.74M USD
Year-over-year change
+140.6%
4-year CAGR
+13.7%

Financing Cash Flow vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's LTM Mar 2026 financing cash flow of $8.35M is the smallest of the 9 companies compared; the peer median is $37.42M.
  • Its year-over-year change of -18.6% is the lowest of 9, against a peer median of +109.0%.
  • Financing cash flow amounts to 590.3% of revenue for COEP, versus a peer median of 459.0%.
COEP Competitors Peer median
Financing Cash Flow for COEP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$126.68M +124.3%-81.5%—
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$79.85M +91.7%-46.3%52.8%
EQEquillium, Inc.LTM Mar 2026$65.68M +25657.6%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$47.24M +93.8%-8.9%14179.4%
CUECue Biopharma, Inc.LTM Mar 2026$27.6M +300.6%-21.2%84.3%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$19.12M +27.6%-10.3%833.6%
OSTXOS Therapies IncorporatedLTM Mar 2026$13.6M +3.6%+1272.4%—
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$9.76M +768.9%+174.4%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$8.35M -18.6%+35.8%590.3%
Peer median (excluding COEP) $37.42M+109.0%-10.3%459.0%

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.45M)(37.57M)(21.27M)(10.88M)(11.92M)
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
Deferred Income Tax5.34M0000
Stock-Based Compensation1.9M0477.5K1.1M1.22M
Change in Working Capital(2.98M)(550.34K)1.73M(125.26K)(1.46M)
Accounts Receivables21.79K(8.08K)(30.9K)(234.74K)(7.35K)
Inventory(422.02K)0000
Accounts Payables(1.58M)(35.07K)1.32M(149.94K)(381.01K)
Other Working Capital(1M)(507.19K)437.31K259.42K(1.07M)
Other Non-Cash Items4.26M33.25M10.79M2.21M2.34M
Operating Cash Flow(4.49M)(3.88M)(7.24M)(6.65M)(8.6M)
Capital Expenditures(1.75M)0000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.75M)0000
Debt Repayment(1.62M)(2.42M)(575K)1.2M771.25K
Common Stock Issued10.14M3.27M5.29M100K12.97M
Common Stock Repurchased(247.17K)0000
Dividends Paid00000
Other Financing Activities(50.9K)4.63M200K500K0
Financing Cash Flow8.22M5.49M4.92M5.71M13.74M
Effect of Forex Changes00000
Net Change in Cash1.98M1.61M(2.32M)(936.25K)5.14M
Free Cash Flow(6.24M)(3.88M)(7.24M)(6.65M)(8.6M)

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.